



Does Concomitant DCIS Affect the Clinical Outcome in Breast Cancer Patients with Invasive Ductal Carcinoma: An Asian Perspective?

Lee WP^{1*}, Shetty SS¹, Seah CMJ¹, Tan PT² and Tan SM¹

¹Division of Breast Surgery, Department of Surgery, Changi General Hospital, Singapore

²Clinical Trials and Research Unit, Changi General Hospital, Singapore

Abstract

Background: Ductal Carcinoma *in Situ* (DCIS) is an established precursor to Invasive Ductal Carcinoma (IDC) and its coexistence with IDC appear to favor reduced biological aggressiveness. Its prognostic implication and ability to affect clinical outcome has been understudied in Asia. This study aims to explore if concomitant DCIS affects the clinical behavior and outcomes among Asians.

Methods: Stage I to III breast cancer patients with histologically proven invasive ductal carcinoma, diagnosed and treated in a single institution from 1 June 2004 to 30 June 2014 were included in this study. Statistical analyses were conducted using χ^2 test, independent T- test, and multivariate logistic regression and Kaplan-Meier test.

Results: A total of 818 patients were identified, including 224 and 594 patients with isolated IDC (No-DCIS) and IDC with coexisting DCIS (IDC-DCIS) respectively. Patients with IDC-DCIS were found to have smaller tumors (median: 22 mm, $p=0.01$), estrogen receptor positivity ($p=0.001$), progesterone receptor positivity ($p<0.001$) and associated with better pathological stage ($p=0.001$). Patients with No-DCIS were 1.6 times more likely to develop disease progression (95% CI: 1.1 to 2.3, $p=0.027$) and subsequently associated with distant recurrences (20.5% vs. 13.6%, $p=0.02$). The breast cancer specific 5 year overall survival rate for patients with No-DCIS and those with IDC-DCIS was 90.9% (95% CI: 86.2% to 94.5%) and 93.7% (95% CI: 91.4 to 95.5%) respectively ($p=0.202$).

Conclusion: The presence of DCIS component in IDC among Asians is associated with favourable tumor biological profile, thereby indicating reduced disease aggressiveness. Our study is the first to report the clinical significance in terms of disease progression and distant recurrences among Asians.

Introduction

Screening mammography has led to a rising detection of early breast cancer, namely Ductal Carcinoma *in Situ* (DCIS). Though the assumption that invasive cancers are likely to derive from pre-existing DCIS [1,2], IDC may still evolve *de novo* in up to 21.4% of cases worldwide. A probable delay in transformation from *in situ* to invasive form is believed to account for tumors with coexisting DCIS demonstrating lesser biological aggressiveness [3,4]. Recent studies have linked tumors with IDC-DCIS with better clinical features such as smaller and lower grade tumors and lower probability of lymph node invasion. Nonetheless, it remains controversial if clinical outcomes such as recurrences and overall survival rates are affected [5,6]. The clinical impact of concomitant DCIS in invasive cancers involving Asians has been understudied. Hence, our study aims to address if coexisting DCIS affects the tumor characteristics and clinical outcome such as recurrences, disease progression and overall survival among Asians.

Materials and Methods

A retrospective analysis was performed on our prospectively collected breast cancer database with an inclusion period from 1 June 2004 to 30 June 2014. This database comprises of patients who were diagnosed and underwent treatment in a specialized breast unit of a single institution. Only patients with definitive histopathology diagnosis for invasive ductal carcinoma were selected for evaluation. Patients diagnosed with metastatic disease were excluded. Patients with bilateral breast cancer were included as two separate study cases. Figure 1 show the inclusion and exclusion criteria

OPEN ACCESS

*Correspondence:

Wai Peng Lee, Division of Breast Surgery, Department of Surgery, Changi General Hospital, Singapore, E-mail: lee.wai.peng@singhealth.com.sg

Received Date: 07 Jul 2021

Accepted Date: 10 Aug 2021

Published Date: 13 Aug 2021

Citation:

Lee WP, Shetty SS, Seah CMJ, Tan PT, Tan SM. Does Concomitant DCIS Affect the Clinical Outcome in Breast Cancer Patients with Invasive Ductal Carcinoma: An Asian Perspective?. World J Breast Cancer Res. 2021; 4(1): 1021.

Copyright © 2021 Lee WP. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

that resulted in our main study cohort of 818 patients.

Data collected include clinical characteristics, histopathological information and the type of surgery performed. The TNM classification was based on the latest edition of the American Joint Committee on Cancer at the time of reporting of the histopathology specimen.

Sentinel Lymph Node Biopsy (SLNB) was performed in all patients with a preoperative diagnosis of infiltrative ductal carcinoma and in the absence of preoperative clinical or radiological evidence of nodal involvement. Axillary lymphadenectomy was performed in patients who had preoperative diagnosis of nodal tumor or macrometastasis on frozen section. Tumor histopathology and the number of lymph nodes involved were evaluated by routine Hematoxylin-Eosin (H&E) staining.

The cases were divided into two groups: Invasive ductal carcinoma (No-DCIS) and Invasive Ductal Carcinoma with Ductal Carcinoma *in Situ* (IDC-DCIS).

Quantitative data are shown as median or mean of their values and their variability is expressed as range or Standard Deviation (SD), as specified for each analysis. Qualitative values are shown as absolute values or percentages. Categorical data was presented in frequency and percentage and association between subjects' characteristics and DCIS were tested using Chi-square test.

Numerical data was presented in mean (standard deviation) and association was tested using independent T-test if normal distribution was fulfilled. Otherwise, data was presented in median and Inter-Quartile Range (IQR) and Mann-Whitney U test was performed to test for the association between subjects' characteristics and DCIS status. Logistic regression was performed to identify the risk of developing disease progression between DCIS and non-DCIS patients.

Survival analysis and duration to disease free progression between DCIS and non-DCIS were performed using Kaplan-Meier with log rank test to assess for statistical differences.

Propensity scores were calculated using a multiple logistic

regression with clinical relevant variables: age, overall tumor stage, menopausal status, hormonal status and cerB2 receptor status. Nearest-neighbor matching with maximum difference of 5% approach in 1:1 fashion was performed to match the propensity scores values of the DCIS and non-DCIS group.

Statistical significance was set at $P < 0.05$. Analysis was performed using SPSS version 21 (IBM Corp., Armonk, USA).

Results

A total of 818 cases from June 1st, 2004 to June 30th, 2014 were included. No-DCIS was present in 224 (27.4%) cases while 594 (72.6%) had IDC-DCIS. The mean age at diagnosis was 55.6 years (42.1 to 69.1). The mean follow up period in our study was 93.7 months (47.2 to 140.2). The ethnic distribution of our study cohort was consistent with our national demographics. The clinicopathological features and the analysis between the two groups are shown in Table 1. Tumors were either T1 (43.8%) or T2 (46.3%). Five hundred and one patients (61.2%) had no nodal involvement (N0). Patients were found to have Stage 1 (32.6%) and 2 (53.2%) cancer, followed by Stage 3 (14.2%). We excluded patients with stage 4.

82.9% had presented with a clinically palpable breast lump. 13.1% were screen detected and hence, asymptomatic (Supplementary Table 1). Others had nipple discharge, breast pain or skin changes and were subsequently evaluated to have cancer. Nine patients presented with bilateral tumors, either synchronous or metachronous.

Lumpectomy was performed in 170 patients while 645 patients had mastectomy as a form of surgical treatment for their condition. One hundred and seventy four patients (78.0%) in the No-DCIS group and 471 (79.6%) in the IDC-DCIS group underwent mastectomy ($p=0.630$).

Though majority of tumors in both groups were found to be grade 3 (48.2%), this result was not statistically significant ($p=0.171$). Similarly, there was no statistical significance upon comparison of the presence of lymphovascular invasion between both groups ($p=0.211$).

The median size of the invasive tumor of the No-DCIS group was




Table 1: Clinicopathologic features of the entire study population and No-DCIS and IDC-DCIS study groups.

Variable	Total (n=818)	No-DCIS (n=224)	IDC -DCIS (n=594)	p value
Age mean years (SD)	55.6 (13.5)	55.3 (14.5)	55.7 (13.1)	p=0.739
Age group				
<40	82 (10.0)	31 (14.5)	51 (8.6)	p=0.826
40-49	224 (27.3)	50 (23.3)	174 (29.3)	
50-59	218 (26.7)	61 (28.5)	157 (26.4)	
60-69	147 (18.0)	41 (19.2)	106 (17.8)	
≥70	147 (18.0)	31 (14.5)	106 (17.8)	
Ethnicity				
Chinese	588 (71.9)	162 (72.3)	426 (71.7)	p=0.397
Malay	135 (16.5)	42 (18.8)	93 (15.7)	
Indian	46 (5.6)	9 (4.0)	37 (6.2)	
Others	49 (6.0)	11 (4.9)	38 (6.4)	
Follow-up duration				
Mean (SD)	93.7 (46.5)	91.6 (49.3)	93.8 (45.5)	p=0.541
Invasive tumour size, median (mm)	24 (15-35)	27 (18-45)	22 (14-31.3)	p<0.001
Tumour status n (%)				
1	358 (43.8)	78 (21.8)	280 (78.2)	p<0.001
2	379 (46.3)	106 (28.0)	273 (72.0)	
3	80 (9.8)	40 (50.0)	40 (50.0)	
Nodal status n (%)				
0	501 (61.2)	130 (25.9)	371 (74.1)	p=0.752
1	211 (25.8)	59 (28.0)	152 (72.0)	
2	93 (11.4)	28 (30.1)	65 (69.9)	
3	1 (0.1)	0 (0.0)	1 (100.0)	
Overall Stage n (%)				
1	267 (32.6)	55 (20.6)	212 (79.4)	p=0.001
2	435 (53.2)	125 (28.7)	310 (71.3)	
3	116 (14.2)	44 (37.9)	72 (62.1)	
Tumour grade n (%)				
1	126 (15.4)	30 (23.8)	96 (76.2)	p=0.171
2	272 (33.3)	62 (22.8)	210 (77.2)	
3	394 (48.2)	114 (28.9)	280 (71.1)	
Presence of lymphovascular invasion n (%)				
Yes	336 (43.4)	80 (39.6)	256 (44.7)	p=0.211
No	439 (56.6)	122 (60.4)	317 (55.3)	
Estrogen receptor n (%)				
Positive	579 (70.8)	135 (23.3)	444 (76.7)	p=0.001
Negative	230 (28.1)	81 (35.2)	149 (64.8)	
Progesterone receptor n (%)				
Positive	494 (60.4)	110 (22.3)	384 (77.7)	p<0.001
Negative	315 (38.5)	106 (33.7)	209 (66.3)	
Her-2 receptor n (%)				
Positive	203 (24.8)	28 (13.8)	175 (86.2)	p<0.001
Negative	562 (68.7)	179 (31.9)	383 (68.1)	
Menopausal status n (%)				
Pre-menopausal	431 (53.9)	119 (54.1)	268 (46.2)	p=0.940
Post-menopausal	369 (46.1)	101 (45.9)	312 (53.8)	
Surgical type n (%)				
Conservation	170 (26.4)	49 (22.0)	121 (20.4)	p=0.630
Mastectomy	645 (73.6)	174 (78.0)	471 (79.6)	




Figure 2: Breast cancer specific 5 year overall survival before (left) and after (right) PSM.

Table 2: Recurrences of the entire study population and No-DCIS and IDC-DCIS study groups.

Variable	Total (n=818)	No-DCIS (n=224)	IDC -DCIS (n=594)	p value
Local recurrence n (%)				
Yes	48 (6.4)	17 (8.1)	31 (5.8)	p=0.746
No	698 (93.6)	192 (91.9)	506 (94.2)	
Distant recurrence n (%)				
Yes	115 (15.5)	42 (20.5)	73 (13.6)	p=0.020
No	627 (84.5)	163 (79.5)	464 (86.4)	

Table 3: Utilization of cox proportion hazard ratio (adjustment for age, overall tumour stage, menopausal status, hormonal receptor and cerB2 status).

	Breast cancer related deaths (%)	Mean, years (95% CI)	HR (95% CI)	p value
IDC-DCIS	25/163 (15.3)	13.30 (12.68, 13.92)	REF	0.608
No-DCIS	21/163 (12.9)	13.56 (12.96, 14.17)	0.86 (0.48, 1.54)	

27 mm while the IDC-DCIS group was 22 mm ($p < 0.001$). Patients with IDC-DCIS were associated with lower T stage ($p < 0.001$) and better overall pathological stage ($p = 0.001$). Furthermore, patients with IDC-DCIS were likely to express positivity in hormonal receptors (estrogen receptor, $p = 0.001$; progesterone receptor, $p < 0.001$) and cerB2 receptor ($p < 0.001$).

The mean duration of follow up was 93.7 months. Clinical outcomes have been summarized in Table 2. One hundred and fifteen distant recurrences were noted, with No-DCIS group having 42 (20.5%) and the IDC-DCIS group having 73 (13.6%) ($p = 0.020$). Forty eight local recurrences were recorded; No-DCIS group had 17 (8.1%) while IDC-DCIS group had 31 (5.8%) ($p = 0.72$).

Patients with No-DCIS were 1.6 times more likely to develop disease progression in contrast to IDC-DCIS (OR: 1.6, 95% CI: 1.1 to 2.6, $p = 0.027$). Patients with IDC-DCIS recorded a longer survival (14.2 years vs. 13.9 years). Log rank test showed that this was not statistically significant ($p = 0.274$). Similarly, patients with IDC-DCIS had an average 12.7 years of disease free progression as compared to those with No-DCIS (12.5 years) ($p = 0.600$).

The breast cancer specific 5 year overall survival rate was performed in 163 pairs matched patients with the aid of propensity score matching (PSM) (Figure 2) and was 92.02% (95% CI 90.9% to 94.7%). Cox proportion hazard ratio showed that patients with IDC-DCIS more likely to progress faster to death (Table 3). Adjustment

by age, overall tumor stage, menopausal status, hormonal receptor and cerB2 status showed no significant difference in the 5 year overall survival rate ($p = 0.608$) (Table 3).

Discussion

Preliminary biological studies are able to demonstrate a biological difference between cancers with No-DCIS and those with IDC-DCIS. The current hypothesis for the presence of concomitant *in situ* disease in such cancers is that tumors do undergo cellular differentiation to transform into an invasive phenotype. This in turn led to the conclusion that this slow progression to the invasive component may then translate into a more favourable clinical prognosis [7,8]. Yet, only a handful of Western studies were able to recognize and associate this to possibly better prognostic features and clinical outcomes. Most yielded insignificant and inconsistent results [9,10]. The clinical significance and role of DCIS among the Asian population remains understudied.

In Singapore, screening mammography is highly subsidized, making it extremely affordable for asymptomatic women. With the increasing awareness for screening mammography, detection of early cancers has also been on the rise. However, currently, the presence of DCIS in invasive cancers has no impact on systemic treatment, which depends solely on the pathological characteristics of the invasive component [11].

There has yet to be a common consensus between the clinical

Supplementary Table 1:

Variable	Total (n=818)	No-DCIS (n=224)	IDC-DCIS (n=594)
Presenting complaint			
Screening			
Mammographic	68 (8.3)	13 (5.8)	55 (24.6)
Ultrasound	18 (2.2)	4 (1.8)	14 (6.3)
Clinical	21 (2.6)	4 (1.8)	17 (7.6)
Symptomatic			
Lump	678 (82.8)	197 (87.9)	481 (58.8)
Nipple discharge	9 (1.1)	0 (0)	9 (1.5)
Nipple changes	5 (0.6)	1 (0.4)	4 (0.7)
Pain	15 (1.8)	4 (1.8)	11 (1.9)
Skin changes	2 (0.2)	0 (0)	2 (0.3)
Tumour laterality			
Left	404 (49.4)	108 (48.2)	296 (49.8)
Right	396 (48.4)	108 (48.2)	288 (48.5)
Bilateral	9 (1.1)	4 (1.8)	5 (0.8)

features and prognostic implications for tumors with concomitant DCIS. With progressive published data among the Westerns, it is widely accepted that patients with IDC-DCIS may present at a younger age with smaller sized tumors with few or no lymph nodal involvement [9,10]. Our results indicated that IDC-DCIS is associated with smaller sized tumors and a lower overall clinical stage, thereby concurring with the hypothesis that tumors with concomitant DCIS were less biologically aggressive.

Likewise, some studies have showed that tumors with concomitant DCIS are likely to express ER, PR and cerB2 positivity as compared to tumors with No-DCIS [13-15], Others disagree [12,15]. Our results showed that IDC-DCIS subjects were likely to express positivity in ER, PR and cerB2 receptors and this was statistically significant. While our data suggest that IDC-DCIS cancers may imply a less aggressive phenotype for patients with hormonal receptor or Her2 receptor positive cancers, we do acknowledge that triple negative malignancies may exhibit different biological behavior.

Researchers have since supported the preliminary theory of this slow evolution in deriving the invasive component and thereby resulting in a possibly better clinical prognosis. This study did demonstrate that the group with No-DCIS had higher percentage of distant recurrences compared to the group with IDC-DCIS (20.6% vs. 13.5%, $p=0.020$). However, we were unable to draw a similar conclusion for local recurrence. This might be attributed to the small total number of patients in our cohort who had developed local recurrences over the surveillance period as a result of better compliance to local radiation therapy prescribed. Our study results also suggest that patients with No-DCIS were 1.6 times more likely to develop disease progression as compared to those with IDC-DCIS, in spite of the adjuvant treatment given. These results add weight to the current speculation that the absence of coexisting DCIS is associated with poorer prognostic features and outcomes among Asian patients, especially in terms of distant recurrences and disease progression. Unfortunately, due to our small sample size of breast cancer related deaths, we were unable to detect a significant difference in the breast cancer specific 5 year overall survival among the 2 groups.

The breast cancer specific 5 year overall survival rate was analyzed with PSM. No significant results were found between the group

with No-DCIS and IDC-DCIS (92.02%, 95% CI = 90.9% to 94.7%, $p=0.608$). PSM is regarded as an advanced statistical technique to minimize any possible confounders in an observational study. It serves to reduce possible treatment assignment bias and mimic randomization [16]. We utilized PSM to assess if concomitant DCIS affects the 5 year breast cancer overall survival rate after adjusting for certain covariates as mentioned above but we were unable demonstrate a more favourable breast cancer specific 5 year overall survival rate. It might be attributed to the fact that both genomic profiles are highly similar [17,18].

Lastly, we do recognize the limitations of this study. Being a retrospective analysis, any incomplete data namely, less detailed histology reports in the early years of the 21st century, had to be excluded. Other information such as patients' details may have been missing during the early days of data entry. Other inherent biases associated with retrospective study have to be considered. Secondly, analysis of tumor specimens had been performed in the absence of central pathologic review, hence establishment of details such as presence of Isolated Tumor Cells (ITC) infiltration and Micrometastases (mic) in lymph nodes were absent. Thirdly, our sample size was too small to demonstrate a significant difference in the 5 year breast cancer specific survival. Unlike the Western studies, the clinical outcomes among Asians such as recurrences and disease free outcomes as a result from tumors with coexisting DCIS has been understudied [19,20]. This study, with a long median follow up of 94 months, is to add weight to current findings and further strengthen the belief that coexisting DCIS does lead to better tumor profile. We are the first to document the clinical significance of concomitant DCIS in the presence of invasive cancers in terms of disease progression and distant recurrences.

Conclusion

With the limited data among Asian population, our study remains the first to demonstrate improved clinical outcomes in terms of disease progression and distant recurrences. Henceforth, this allows clinicians to better prognosticate and consider vigilant clinical surveillance of patients diagnosed with isolated IDC in remission.

Ethics Approval and Consent to Participate

This study had received the approval of the institutional ethics committee prior to its commencement (IRB Ref No: 2019/2884). A waiver of consent was permitted.

Availability of Data and Materials

The datasets used during the current study are available from the corresponding author on reasonable request.

References

- Vaidya Y, Vaidya P, Vaidya T. Ductal carcinoma in situ of the breast. *Indian J Surg.* 2015;77(2): 141-6.
- Sgroi DC. Preinvasive breast cancer. *Annu Rev Pathol.* 2010;5:193-221.
- Dzierzanowski M, Melville KA, Barnes PJ, MacIntosh RF, Caines JS, Geoffrey A. Porter ductal carcinoma *in situ* in core biopsies containing invasive breast cancer: Correlation with extensive intraductal component and lumpectomy margins. *J Surg Oncol.* 2005;90(2):71-6.
- Logullo AF, Godoy AB, Mourão-Neto M, Simpson AJG, Nishimoto IN, Brentani MM. Presence of ductal carcinoma *in situ* confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. *Braz J Med Biol Res.* 2002;35(8):913-9.

5. Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. *Breast*. 2014;23(4):346-51.
6. Meseguer PC, Zapardiel I, Gimferrer MC, Tundidor SG, Casas FT, García IR, et al. Influence of the *in situ* component in 389 infiltrating ductal breast carcinomas. *Breast Cancer*. 2013;20(3):213-7.
7. Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an *in situ* component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. *Br J Cancer*. 2010;102(9):1391-6.
8. Chagpar AB, McMasters KM, Sahoo S, Edwards MJ. Does ductal carcinoma *in situ* accompanying invasive carcinoma affect prognosis? *Surgery*. 2009;146(4):561-7;discussion567-8.
9. Sebastián CS, Mur CG, Ciria SC, Cuesta DSR, Bañeres BG. Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma *in situ* as a prognostic factor. *Radiologia*. 2016;58(4):283-93.
10. Goh CW, Wu J, Ding S, Lin C, Chen X, Huang O, et al. Invasive Ductal Carcinoma with coexisting Ductal Carcinoma *in situ* (IDC/DCIS) versus pure Invasive Ductal Carcinoma (IDC): A comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. *J Cancer Res Clin Oncol*. 2019;145(7):1877-86.
11. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016;14(3):324-54.
12. Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. *Breast*. 2014;23(4):346-51.
13. Kim JY, Han W, Moon HG, Park IA, Ahn SK, Kim J, et al. Grade of ductal carcinoma *in situ* accompanying infiltrating ductal carcinoma as an independent prognostic factor. *Clin Breast Cancer*. 2013;13(5):385-91.
14. Wong H, Lau S, Yau T, Cheung P. Presence of an *in situ* component is associated with reduced biological aggressiveness of size matched invasive breast cancer. *Br J Cancer*. 2010;102(9):1391-6.
15. Logullo AF, Godoy AB, Simpson AJG, Nishimoto IN, Brentani MM. Presence of ductal carcinoma *in situ* confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. *Braz J Med Biol Res*. 2002;35(8):913-9.
16. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. *Am J Epidemiol*. 2006;163(12):1149-56.
17. Schorr MC, Pedrini JL, Savaris RF, Zettler CG. Are the pure *in situ* breast ductal carcinomas and those associated with invasive carcinoma the same? *Appl Immunohistochem Mol Morphol*. 2010;18(1):51-4.
18. Iakovlev VV, Arneson NC, Wong V, Wang C, Leung S, Iakovleva G, et al. Genomic differences between pure ductal carcinoma *in situ* of the breast and that associated with invasive disease: A calibrated study. *Clin Cancer Res*. 2008;14(14):4446-54.
19. Chen H, Bai F, Wang M, Zhang M, Zhang P, Wu K. The prognostic significance of co-existence ductal carcinoma *in situ* in invasive ductal breast cancer: A large population-based study and a matched case-control analysis. *Ann Transl Med*. 2019;7(18):484.